EU backs Nycomed's Daxas in deadly lung disease
* First new treatment type for COPD in over a decade * Important step towards possible IPO, timeline not changed
ZURICH, July 6 (Reuters) - Nycomed's [NYCMD.UL] lung drug Daxas has won European Union backing to treat patients with chronic obstructive pulmonary disease, bringing to market the first new type of treatment for the disease in over a decade.
Daxas, a once-daily oral tablet, is expected to be launched soon in Britain and Germany, the privately owned Swiss drugmaker said on Tuesday, possibly helping it to carve out a niche in the multibillion-dollar worldwide COPD market.
Nycomed, which is aiming for an eventual IPO, struck a deal with Merck & Co (MRK.N) to help sell its key drug in Europe and Canada earlier this year, while Forest Laboratories FRX.N holds U.S. rights to the drug, also known as roflumilast. [ID:nLDE63P05Q]
The approval was widely expected after Daxas got a green light from European regulators in April recommending it for approval as a maintenance treatment for severe COPD, despite a rebuff in the United States. [ID:nLDE63M10W]
"This is an important step towards a possible IPO, but it does not change the timeline," said a spokeswoman for Nycomed.
Nycomed has said it could possibly list in the Swiss stock exchange in 2011 at the earliest, but has so far declined to give a concrete timeframe.
Daxas is also pivotal for Forest, which is trying to build its portfolio ahead of the 2012 patent expiration for its huge-selling antidepressant Lexapro.
Industry analysts have estimated peak annual sales could hit $500 million or more.
According to WHO estimates, 80 million people suffer from moderate to severe COPD worldwide and more than 3 million died from the disease in 2005.
Nycomed, which had sales of 3.2 billion euros ($4.29 billion) in 2009, is majority-owned by four private equity firms, led by Nordic Capital. The other are Credit Suisse's DLJ Merchant Banking, Coller International Partners and Avista. (Reporting by Katie Reid; Editing by Jon Loades-Carter) ($1 = 0.7453 euro)
Trending On Reuters
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video